Descrizione del progetto
Nuovo trattamento per le infezioni polmonari batteriche farmacoresistenti
La crescente resistenza a molti antibiotici e l’insorgenza dei batteri multifarmaco-resistenti richiede lo sviluppo di terapie antibatteriche alternative. Oggi, la resistenza batterica al farmaco è la principale causa di morbilità e mortalità nei pazienti con infezioni polmonari da fibrosi cistica e acquisite in ospedale. Il progetto, finanziato dall’UE, svilupperà un nuovo trattamento per le infezioni polmonari batteriche utilizzando sorgenti luminose inalabili che stimolano i fotosensibilizzanti batterici endogeni (porfirine), uccidendo i batteri mediante l’effetto fotodinamico (produzione locale di ossigeno citotossico reattivo). Il trattamento sarà sicuro per i tessuti ospiti ed efficace contro gli agenti patogeni farmacoresistenti. La ricerca comporta lo sviluppo di particelle luminescenti inalabili, del metodo di somministrazione nei polmoni e della valutazione dei parametri di trattamento nei modelli clinici rilevanti.
Obiettivo
Light4lungs addresses the problem of antimicrobial resistance in the treatment of chronic lung infections, which are the leading cause of morbidity and mortality in patients with diseases such as cystic fibrosis and hospital-acquired lung infections. The goal is to develop a novel therapeutic scheme for the treatment of the infections, whereby antibiotics will be replaced by inhalable light sources that will excite bacterial endogenous photosensitisers (e.g. iron-free porphyrins), eliminating the pathogenic bacteria by the photodynamic effect (local production of cytotoxic reactive oxygen species by the combined action of light, a photosensitiser and oxygen) irrespective of its multidrug resistance profile. The treatment will be safe for the host tissue because of its lack of self-photosensitising ability.
Light4Lungs departs from current paradigms: (1) bacterial infections will be treated without antibiotics, which will be replaced by breathable light sources; (2) bacteria will be eliminated without any externally-added drug, taking advantage of endogenous photosensitisers; (3) a breathable light source will be used to elicit the therapeutic action, avoiding the use of invasive physical tethers to deliver light to the lungs. The project encompasses the development of particles with persistent luminescence, the aerosol technology for activation and delivery to the lungs, and the definition of the treatment parameters through toxicity and efficacy tests in clinically relevant models of respiratory infections. The project combines several different scientific expertise from photonics to medicine. The results will be useful for patients with recalcitrant respiratory tract bacterial infections and will eventually be extended to other diseases in the lungs and in other internal organs. The impact reaches beyond antimicrobial resistance itself and will affect many other fields such as healthcare, nanomedicine, materials science and nanotechnology and lightning
Campo scientifico
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Parole chiave
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-FETOPEN-2018-2019-2020-01
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
08017 Barcelona
Spagna